Healthcare / Medical Instruments & SuppliesBSE
$60.70
-1.37 (-2.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-39.9M · quality 49.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$306M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.5%
↓Gross Margin
29.8%
↓Debt/Equity
0.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+15.5%
FCF CAGR
—
FCF margin
-5.1%
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.09B · net income $-70.4M · FCF $-55.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.09B | $1.09B | $882.5M | $753.8M | $707.5M |
| Net Income | $-70.4M | $-70.4M | $-28.1M | $-1.7M | $12.7M |
| EBITDA | $-20.7M | $-20.7M | $15.1M | $42.6M | $57.3M |
| EPS | -13.98 | -13.98 | -5.58 | -0.33 | 2.53 |
| Gross Margin | 29.8% | 29.8% | 28.7% | 32.0% | 32.0% |
| Operating Margin | -5.2% | -5.2% | -2.6% | 1.2% | 3.3% |
| Net Margin | -6.5% | -6.5% | -3.2% | -0.2% | 1.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.28 | 0.28 | 0.19 | 0.18 | 0.19 |
| Cash Flow | |||||
| Free Cash Flow | $-55.8M | $-55.8M | $21.4M | $-39.9M | $3.1M |
| Returns | |||||
| ROE | -13.5% | -13.5% | -4.7% | -0.3% | 2.0% |
| Valuation | |||||
| P/E | — | — | — | — | 35.67 |
| EV/EBITDA | — | — | 38.08 | 16.04 | 8.96 |
| P/B | 0.59 | 0.59 | 0.82 | 0.95 | 0.72 |
| Growth & Yield | |||||
| Revenue Growth | 23.5% | 23.5% | 17.1% | 6.6% | — |
| EPS Growth | -150.5% | -150.5% | -1590.9% | -113.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.58 → -13.98
Residual
-18.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.